1800 Alzheimer's patients at varying stages participated in the study.
There is some good news for Alzheimer’s patients as an experimental treatment has demonstrated great success in delaying the decrease in cognitive and functional abilities by roughly 27%, according to the drug’s manufacturers.
Lecanemab, a medicine created by American corporation Biogen and Japanese pharmaceutical company Eisai, demonstrated tremendous promise in clinical testing, and the companies anticipate that it will be approved by 2023. There were some side effects of the medication, such as brain swelling and haemorrhage, but Eisai claimed they were well within their predicted ranges.
A symposium on Alzheimer’s will be held in San Francisco in November, according to Eisai, and the data from the trial findings will be presented there.
The two firms previously attempted to market a medicine comparable to this one, named Aduhelm. Although the US Food and Drug Administration (FDA) had approved it, it was discontinued because Medicare did not fund it.
Lecanemab and Aduhelm are chemically identical, but the latter has, according to the firms, “reduced the pace of cognitive deterioration in persons with early illness by 27% over 18 months.”
Parvathy Sukumaran 
